# AIM ImmunoTech Inc. (AIM) — capital_raise/atm_program [announced]
Source: SEC API (secapi.ai) · situation sit_11fec91b18530919ad4e · retrieved 2026-08-12T06:58:55.652Z

## Overview
AIM ImmunoTech Inc. is a biological products company engaged in the development and commercialization of immunotherapeutic treatments.

AIM ImmunoTech Inc. terminated its Equity Distribution Agreement with Maxim Group LLC, effective August 15, 2026. The agreement, originally dated April 1, 2025 and amended on April 10, 2026, permitted the company to conduct at-the-market offerings of common stock. From April 1, 2025 to July 31, 2026, the company sold 3,200,736 shares for aggregate gross proceeds of approximately $2.8 million under the agreement. The termination is mutual and incurs no penalties.

## Terms
- Counterparty: Maxim Group LLC · Deal value: $2.8M

## Key dates
- Announced 2026-08-05

## Timeline
- 2026-08-05 · 8-K (0001493152-26-036104): 8-K - AIM ImmunoTech Inc. — *AIM ImmunoTech Inc. is a biological products company engaged in the development and commercialization of immunotherapeutic treatments.* AIM ImmunoTech Inc. terminated its Equity Distribution Agreement with Maxim Group LLC, effective August 15, 2026. The agreement, originally dated April 1, 2025 and amended on April 10, 2026, permitted the company to conduct at-the-market offerings of common stock. From April 1, 2025 to July 31, 2026, the company sold 3,200,736 shares for aggregate gross proceeds of approximately $2.8 million under the agreement. The termination is mutual and incurs no penalties.
  https://www.sec.gov/Archives/edgar/data/946644/0001493152-26-036104.txt

## Citations
- 0001493152-26-036104 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000149315226036104